This company seems to have been delisted
Reason: Acquired by Immedica
Last recorded trade on: April 16, 2025
Source: https://www.immedica.com/en/press/immedica-completes-acquisition-marinus-pharmaceuticals-inc-2299708
Reason: Acquired by Immedica
Last recorded trade on: April 16, 2025
Source: https://www.immedica.com/en/press/immedica-completes-acquisition-marinus-pharmaceuticals-inc-2299708
Marinus Pharmaceuticals
MRNS
HK$4.32
Share price
0.00%
Change (1 day)
-62.14%
Change (1 year)
Categories
Revenue for Marinus Pharmaceuticals (MRNS)
Revenue in 2024 (TTM): HK$0.24 Billion
According to Marinus Pharmaceuticals's latest financial reports the company's current revenue (TTM 
) is HK$0.24 Billion. In 2023 the company made a revenue of HK$0.24 Billion an increase over the revenue in the year 2022 that were of HK$0.19 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Marinus Pharmaceuticals from 2013 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 (TTM) | HK$0.24 B | 1.46% |
| 2023 | HK$0.24 B | 21.58% |
| 2022 | HK$0.19 B | 66.37% |
| 2021 | HK$0.11 B | 798.42% |
| 2020 | HK$13.31 M | |
| 2019 | N/A | |
| 2018 | N/A | |
| 2017 | N/A | |
| 2016 | N/A | |
| 2015 | N/A | |
| 2014 | N/A | |
| 2013 | N/A |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 AcelRx Pharmaceuticals
ACRX | HK$5.1 M | -97.93% | 🇺🇸 USA |
 Eagle Pharmaceuticals
EGRX | HK$2.02 B | 718.51% | 🇺🇸 USA |
 Endo International
ENDPQ | HK$15.78 B | 6,292.67% | 🇮🇪 Ireland |
 Supernus Pharmaceuticals
SUPN | HK$5.24 B | 2,022.92% | 🇺🇸 USA |